ProCE Banner Activity

PALOMA-2 Final OS Analysis: Addition of Palbociclib to Frontline Letrozole in Postmenopausal ER+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
Final results showed no significant difference in overall survival with the addition of palbociclib to frontline letrozole in postmenopausal patients with ER-positive/HER2-negative breast cancer.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab